Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Tru Niagen Review
Its annual report says the product raises NAD+ in blood and tissue. Its marketing says it can revolutionise the way you age. Only one of those was written by lawyers.
Tru Niagen
Best Substantiated, Unproven BenefitThe dossier is the best in this series: food-grade Niagen has twice been reviewed under the FDA’s NDI programme, notified as GRAS, and authorised by Health Canada, the European Commission, Turkey’s agriculture ministry and Australia’s TGA. Pharmaceutical-grade Niagen is FDA-authorised for 503B compounding, with prescription IV formulations. Most supplements have no premarket review at all.
But read the 10-K, not the advert: the filing says oral NR “significantly increases NAD+ levels in blood and tissue” — a biomarker. It does not say raising NAD+ makes you healthier. The marketing promises to “revolutionize the way you age”. And “backed by 2 Nobel Prize winners” is one laureate chairing an advisory board — the brand’s own site says one.
Checked 8 August 2026: 300mg $49.00 (from $39.20 subscribed) — about $588/year at list, $470 subscribed; Pro 1,000mg $116.00; 150mg 120ct $94.00; stick packs $58.00. Subscription is 20% off with free shipping, stated as always rather than tapering. Niagen Bioscience (formerly ChromaDex) trades as NAGE on Nasdaq: net sales $129.4m in 2025, up 30%, equity $76.5m — against a $164.5m accumulated deficit.
Affiliate disclosure: GLP1Drugs.org earns 2.5% if you buy through the links on this page — roughly a dollar on a $49 order. Verified 8 August 2026.
Visit Tru NiagenOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
2
FDA NDI Reviews Passed
NAD+
What It Proves It Raises
$470
Per Year, Subscribed
1
Nobel Laureate, Not Two
What We Verified
Regulatory and financial statements read directly from Niagen Bioscience's Form 10-K for the year ended 31 December 2025, filed 4 March 2026; prices from truniagen.com. 8 August 2026.
The Regulatory Dossier Is The Best We Have Seen
Per its own annual report, food-grade Niagen has twice been successfully reviewed under the FDA's new dietary ingredient programme, notified to the FDA as GRAS, and authorised by Health Canada, the European Commission, Turkey's agriculture ministry and Australia's TGA
And Pharmaceutical-Grade Niagen Is FDA-Authorised For 503B Compounding
The filing states pharmaceutical-grade Niagen is authorised by the FDA for compounding by 503B outsourcing facilities, with intravenous and injectable formulations dispensed on prescription. No other supplement in this series has that standing
But Read What The 10-K Actually Claims
"Data from numerous preclinical studies and human clinical trials demonstrate that orally administered NRC significantly increases NAD+ levels in blood and tissue." That is a biomarker claim. It does not say raising NAD+ produces a health outcome
The Marketing Goes Considerably Further
The affiliate copy promises "the nutrient that can revolutionize the way you age". SEC filings carry legal consequences for overstatement; marketing does not. When the same company describes its product both ways, believe the filing
"Two Nobel Prize Winners" Is One, Chairing A Board
The 10-K names Dr Roger Kornberg, Nobel Laureate, as chair of the scientific advisory board, alongside Dr Charles Brenner, who discovered NR as an NAD+ precursor. The brand's own site says "a Nobel Prize-winning biochemist" — singular
The Company Is Real And Growing, With Caveats
Niagen Bioscience, formerly ChromaDex, trades as NAGE on Nasdaq. Net sales rose 30% to $129.4m in 2025, equity is $76.5m — but the accumulated deficit is $164.5m and it warns it may not sustain profitability
Filing Versus Advert
The same company, describing the same product, to two different audiences. Both quotations are verbatim.
| Claim | Where It Appears | What It Actually Establishes |
|---|---|---|
| “Significantly increases NAD+ levels in blood and tissue” | The 10-K | Well replicated. The part of the science that holds |
| “Can revolutionize the way you age” | Marketing copy | Not demonstrated — the biomarker is not the outcome |
| “Backed by 2 Nobel Prize winners” | Affiliate material | One laureate chairs the advisory board; the site says one |
| “500+ Published Scientific Studies” | The website | Includes preclinical work; 45+ are human studies on Niagen |
For GLP-1 fatigue and lean mass, the things with trial support are protein, resistance training and testing for what is actually low. Our side-effects guide covers the fatigue picture, and our provider rankings cover prescribers who will order the bloods.
Pros & Cons
Pros
- ✓Food-grade Niagen has twice been successfully reviewed under the FDA's new dietary ingredient (NDI) programme and successfully notified to the FDA as GRAS
- ✓Authorisations or approvals from Health Canada, the European Commission, the Turkish Ministry of Agriculture and Australia's Therapeutic Goods Administration, plus Brazilian approval for medical foods
- ✓Pharmaceutical-grade Niagen is stated to be FDA-authorised for compounding by 503B outsourcing facilities, with prescription IV and injectable formulations
- ✓The claim that oral NR raises NAD+ in blood and tissue is well replicated and is the part of the science that genuinely holds
- ✓The scientific advisory board is chaired by a Nobel laureate and includes the scientist who discovered NR as an NAD+ precursor
- ✓The site cites 45-plus human clinical studies on Niagen itself, which is the meaningful figure rather than the wider literature count
- ✓Niagen Bioscience is Nasdaq-listed and files audited accounts, so its finances can be checked rather than taken on trust
- ✓Net sales grew 30% to $129.4 million in 2025, with a five-year compound growth rate of 18% — this is a substantial business, not a dropshipper
- ✓Shareholders' equity of $76.5 million against $106.4 million of total assets, and net income recorded in both 2024 and 2025
- ✓The subscription is 20% off all orders with free shipping, stated as "always" rather than tapering after a few deliveries
- ✓A range of doses from 150mg to 1,000mg lets you start low rather than being pushed to the highest serving
- ✓Its own risk factors acknowledge competitors overstating ingredient levels — a company aware that its category has a labelling problem
Cons
- ✕The gap between the biomarker and the benefit is unresolved: raising NAD+ is demonstrated, but that raising it improves health outcomes is not established
- ✕The marketing promise to "revolutionize the way you age" is considerably stronger than anything in the company's own SEC filing
- ✕The affiliate material claims backing by "2 Nobel Prize winners"; the brand's own site says one, and the 10-K names one as advisory board chair
- ✕A Nobel laureate chairing a scientific advisory board is scientific governance, not evidence that the product works
- ✕$49 a month for the 300mg serving is about $588 a year at list, or roughly $470 on subscription
- ✕The Pro 1,000mg pack is $116, and the 150mg 120-count is $94 — this is an expensive habit at any dose
- ✕The accumulated deficit stands at $164.5 million and the company explicitly warns it may not sustain profitability
- ✕Nothing here is demonstrated to help GLP-1 fatigue, lean mass loss, nausea or any other treatment side effect
- ✕Some trials of NR have not shown improvements in muscle function or metabolic outcomes despite raising NAD+ — the honest picture is mixed
- ✕HSA/FSA acceptance runs into the IRS's March 2024 warning that supplements generally do not qualify as medical expenses
- ✕"500+ Published Scientific Studies" counts preclinical and mechanistic work, not 500 trials of this product in people
- ✕The FDA's September 2025 decision on NMN, which the company flags as a competitive risk, means cheaper rival precursors are now lawful to sell
Our Verdict
4.0 / 5 — the most rigorously substantiated supplement in this series, sold on a promise its own filings do not make.
After a month of reviewing supplement brands whose evidence turned out to be perception surveys, twelve-person studies and proprietary blends, Tru Niagen is a different proposition and we want to be clear about that first. Its regulatory dossier is the strongest we have encountered: according to its own annual report, food-grade Niagen has twice been successfully reviewed under the FDA's new dietary ingredient programme, has been successfully notified to the FDA as GRAS, and holds approvals or authorisations from Health Canada, the European Commission, the Turkish Ministry of Agriculture and Australia's Therapeutic Goods Administration, plus Brazilian approval for medical foods. More unusually still, pharmaceutical-grade Niagen is stated to be FDA-authorised for compounding by 503B outsourcing facilities, with intravenous and injectable formulations dispensed on prescription. Most dietary supplements reach the market with no premarket review of any kind. The scientific advisory board is chaired by a Nobel laureate and includes the scientist who first identified NR as an NAD+ precursor. And because the parent, Niagen Bioscience — formerly ChromaDex, trading as NAGE on Nasdaq — files audited accounts, you can check the business rather than trusting it: net sales of $129.4 million in 2025, up 30%, with shareholders' equity of $76.5 million.
Now the thing that decides whether you should buy it, and it comes from the company's own words rather than ours. The 10-K states that 'orally administered NRC significantly increases NAD+ levels in blood and tissue'. That is a biomarker claim, and it is well supported — nicotinamide riboside does reliably raise blood NAD+ in humans, which is more than most supplement ingredients can demonstrate. What the filing conspicuously does not claim is that raising NAD+ improves health, energy, muscle or the trajectory of ageing. The marketing does: the affiliate material we were given describes Niagen as 'the nutrient that can revolutionize the way you age'. Those two sentences describe the same product to two audiences, and only one of them was drafted under securities liability. Several trials of NR have raised NAD+ without improving muscle function or the metabolic endpoints researchers hoped for, which is what you would expect if the biomarker is not the limiting factor. So this is a product that demonstrably does what it says biochemically, sold on an inference that has not been established. That is not fraud; it is the entire NAD+ category, and this is the most honest version of it.
Three smaller notes. The 'backed by 2 Nobel Prize winners' line in the affiliate copy resolves to one laureate chairing the scientific advisory board — the brand's own website says 'a Nobel Prize-winning biochemist', singular — and a Nobel Prize for work on eukaryotic transcription does not transfer to a supplement's efficacy. The '500+ Published Scientific Studies' figure includes preclinical and mechanistic work; the meaningful number the site also gives is 45-plus human clinical studies on Niagen itself. And on the finances, the company's own risk factors are worth quoting: 'While we have recorded a net income in both 2025 and 2024, we may not be able to sustain profitability in future periods' — against an accumulated deficit of $164.5 million. That is comfortable enough for someone buying a monthly subscription, but it is not the picture the growth headline alone suggests. One correction to the record while we are here: some stock-data sites show the old CDXC ticker ceasing to trade in March 2025, which was the renaming to NAGE rather than a delisting. We checked the filings directly.
So: buy it if you want the best-characterised NAD+ precursor from the most accountable supplier in the category, you have read the biomarker caveat and accept it, and $470 to $588 a year is comfortable. Start at 150mg or 300mg rather than the 1,000mg Pro. Do not buy it for GLP-1 fatigue or to protect lean mass — that is protein, resistance training and a blood test, none of which cost $49 a month. Check your plan before relying on HSA/FSA eligibility. We earn 2.5%, about a dollar on a $49 order, and this is one of very few supplement pages in this series where our conclusion is that the product is broadly what it claims — provided you read what the company tells its investors rather than what it tells you.
Visit Tru NiagenFrequently Asked Questions
Does Tru Niagen actually do anything?
It reliably does one thing, and whether that one thing matters is genuinely unresolved — and the most honest description of that comes from the company itself. Its annual report states: 'Data from numerous preclinical studies and human clinical trials demonstrate that orally administered NRC significantly increases NAD+ levels in blood and tissue.' Read that carefully, because it is precisely worded. It claims the product raises a biomarker. It does not claim that raising the biomarker makes you healthier, live longer, feel more energetic or age differently. That distinction is the entire question with NAD+ supplements. The first half is well established: nicotinamide riboside does raise blood NAD+ in humans, replicated across multiple trials, and that is more than most supplement ingredients can say. The second half — that raising NAD+ produces clinical benefit — is where the evidence thins considerably, and where trials have returned mixed results, including studies that raised NAD+ without improving muscle function or metabolic markers. So the fair summary is: this is a supplement that demonstrably does what it says biochemically, sold on an implication about ageing that has not been demonstrated. We would rather tell you that plainly than either dismiss it as snake oil, which it is not, or repeat the marketing, which outruns the science.
Why do you keep quoting the SEC filing rather than the website?
Because they say different things, and one of them carries legal consequences for exaggeration. A company's annual report on Form 10-K is filed with the Securities and Exchange Commission, reviewed by lawyers and auditors, and carries liability if it materially misleads investors. Marketing copy carries no comparable exposure. So when the same company describes the same product in both places, the filing is the more conservative and more reliable statement of what it actually believes it can support. Here the contrast is instructive. The 10-K says orally administered NR 'significantly increases NAD+ levels in blood and tissue' — a biomarker. The affiliate material we were given describes Niagen as 'the nutrient that can revolutionize the way you age'. Those are not the same claim, and the difference is not a rounding error. We are not accusing the company of anything improper: consumer marketing is allowed to be aspirational within the rules, and the site does carry the structure-function language you would expect. But if you are deciding whether to spend $470 a year, the version written for people who can sue is the one to read. This is a technique we would recommend for any listed supplement company, and it is one of the reasons a Nasdaq listing is genuinely useful to a consumer rather than just a credibility badge.
How good is the regulatory standing?
The best of any supplement we have reviewed in this series, and it deserves saying without hedging. According to its annual report, food-grade Niagen 'has twice been successfully reviewed under the FDA's new dietary ingredient (NDI) program, has been successfully notified to the FDA as GRAS, and has received approvals or authorizations from Health Canada, the European Commission, the Turkish Ministry of Agriculture, and the Therapeutic Goods Administration (TGA) of Australia', and has also been approved for inclusion in medical foods by the Brazilian health regulator. To put that in context: most dietary supplements are sold with no premarket review whatsoever, and the great majority of ingredients we have assessed this month had none of this. Two successful NDI notifications plus a GRAS notification plus five national regulators is a serious dossier. More striking still, the filing states that pharmaceutical-grade Niagen 'is authorized by the U.S. Food and Drug Administration (FDA) for compounding by 503B outsourcing facilities', with intravenous and injectable Niagen formulations available on prescription. A supplement ingredient that also exists in a pharmacy-compounded injectable form is genuinely unusual. What none of this establishes is efficacy. Regulatory clearance of this kind speaks to safety and lawful marketing, not to whether the product improves your health — a distinction the company observes more carefully in its filings than its marketing does.
What about the "two Nobel Prize winners"?
It resolves to one Nobel laureate chairing an advisory board, which is real and impressive and not the same thing as the marketing implies. The affiliate material we were given says Tru Niagen is 'backed by 2 Nobel Prize winners'. The brand's own website says 'a Nobel Prize-winning biochemist' — singular. And the annual report is specific: 'Our Scientific Advisory Board, chaired by Dr. Roger Kornberg, Nobel Laureate and Stanford Professor, includes distinguished scientists such as Dr. Charles Brenner, discoverer of NR as an NAD+ precursor, and experts from Harvard, UC Davis, USC, Scripps Research, and the NIH.' Two observations. First, having the scientist who discovered NR as an NAD+ precursor on your advisory board is a genuinely strong signal about the seriousness of the science programme, and we would not want to diminish it. Second, a Nobel Prize is awarded for a specific body of work, and chairing a company's advisory board does not transfer that authority to the company's product — Roger Kornberg's prize was for work on eukaryotic transcription, not NAD+ metabolism. So read 'backed by Nobel laureates' as evidence of good scientific governance, which it is, rather than as evidence the supplement works, which it is not. That the affiliate copy inflates one laureate to two is a small thing, but it is the sort of small thing worth checking when the rest of the pitch is about scientific rigour.
Would it help with GLP-1 side effects or muscle loss?
There is no demonstrated benefit, and we would not spend $470 a year on the hope. The plausible-sounding pitch would go: GLP-1 treatment causes fatigue and lean mass loss, NAD+ is central to cellular energy metabolism and mitochondrial function, therefore an NAD+ precursor should help. It is a reasonable hypothesis and it is not evidence. Several trials of nicotinamide riboside in older adults have raised NAD+ without producing improvements in muscle function or the metabolic outcomes researchers were looking for, which is exactly the pattern you would expect if the biomarker is not the bottleneck. On lean mass specifically, the interventions with actual trial support are unglamorous: adequate protein — roughly 45% of the weight lost in the STEP 1 body-composition analysis was lean tissue — and resistance training. Neither costs $49 a month. On fatigue, the common causes during GLP-1 treatment are under-eating, dehydration and nutrient gaps including iron and B12, all of which are testable and correctable, and none of which an NAD+ precursor addresses. So our advice is the same as it has been throughout this series: get bloods done, hit your protein, lift something twice a week, and talk to your prescriber if fatigue persists. If after all that you want to take Niagen for its own sake, it is a well-made product from a serious company — just do not buy it as a treatment for something the evidence does not support.
What does it cost?
More than most people expect, and the per-day figure is the one to look at. Checked on 8 August 2026: Tru Niagen 300mg, described as 'the original — our minimum daily recommended serving', is $49.00 for 30 capsules or from $39.20 on subscription, with 90 and 180 counts also available. That is $1.63 a day at list or about $1.31 subscribed — call it $588 or $470 a year. Tru Niagen Pro 1,000mg is $116.00 for 60 capsules, from $92.80. Tru Niagen 150mg is $94.00 for 120 capsules, from $75.20, which works out cheapest per day but at half the standard serving. The 300mg Stick Packs are $58.00 for 30, from $46.40, and Tru Niagen Beauty, a 100mg Niagen product with added beauty actives, is $49.00, from $39.20. The subscription is 20% off all orders with free shipping, and the site describes that as 'always' rather than an introductory rate that halves after three deliveries — a genuine mark in its favour after several brands we criticised this month for exactly that. The site also states it now accepts HSA/FSA, which carries the caveat we have raised elsewhere: the IRS warned in March 2024 that a letter of medical necessity does not make a supplement a qualified medical expense, and a disallowed distribution becomes taxable with an additional penalty. Check with your plan administrator rather than assuming.
Is the company financially sound?
Growing well, profitable recently, and carrying a long history of losses — and because it is listed you can check all three rather than guessing. Niagen Bioscience, Inc., formerly ChromaDex Corp., trades as NAGE on the Nasdaq Capital Market and files audited accounts; its most recent quarterly report was filed on 4 August 2026. For the year ended 31 December 2025 it reported total net sales of $129.4 million, up 30% or $29.8 million on 2024, with Tru Niagen sales up $20.9 million or 27% driven by a $16.2 million increase in e-commerce, and a compound annual growth rate of 18% across 2021 to 2025. Shareholders' equity stood at $76.5 million against $106.4 million of total assets, and it recorded net income in both 2024 and 2025. The caveats are in its own risk factors, which we would rather quote than paraphrase: 'While we have recorded a net income in both 2025 and 2024, we may not be able to sustain profitability in future periods. Our history of net losses and negative cash flow have had, and may continue to have, an adverse effect on our stockholders' equity and working capital.' The accumulated deficit is $164.5 million. Practically, for someone buying a monthly subscription, that picture is comfortable — this is not a company whose ability to ship next month is in question. One aside: some stock-data sites show the old CDXC symbol as having stopped trading in March 2025. That was the ticker change to NAGE, not a delisting; we checked the filings directly.
How does it compare with NMN and cheaper NAD+ products?
Better substantiated, more expensive, and the competitive landscape has just shifted — a change the company itself flags. Until recently, nicotinamide mononucleotide sat in regulatory limbo in the United States, and Niagen's NDI and GRAS position was a substantial commercial moat. Then, as we noted when reviewing another NAD+ brand earlier this month, the FDA determined in September 2025 that NMN may be lawfully marketed as a dietary ingredient. Niagen Bioscience lists this in its own risk factors: 'In September 2025, the FDA determined that nicotinamide mononucleotide (NMN) may be lawfully marketed as a dietary ingredient. If this determination is not overturned or superseded, it may introduce additional channels of competition in certain product categories.' So you will see more NMN products, often cheaper. Two things to hold on to. NR and NMN are different molecules with different evidence bases, and the human data on NR raising NAD+ is more extensive — but 'more extensive' still stops at the biomarker for both. And the company's risk factors also warn that 'some competitors may engage in misleading marketing practices, including mislabeling their products by overstating ingredient levels', which is a real problem in this category and an argument for buying from someone with a verifiable supply chain if you buy at all. Against generic nicotinamide or plain niacin, which are cents per day, Niagen is vastly more expensive and better characterised.
So who should buy it?
Buy it if you want an NAD+ precursor from the most rigorously substantiated supplier in the category, you have read the biomarker caveat above and accept it, and $470 to $588 a year is money you are comfortable spending on a hypothesis. On those terms this is a defensible purchase: two FDA NDI reviews, a GRAS notification, five national regulators, a pharmaceutical grade authorised for 503B compounding, 45-plus human clinical studies on the ingredient itself, a Nasdaq-listed parent whose accounts you can read, and a subscription discount that does not quietly expire. Start at 150mg or 300mg rather than the 1,000mg Pro, since there is no reason to assume the highest serving is the best one. Do not buy it to fix GLP-1 fatigue or to protect lean mass — get bloods done, eat the protein, do the resistance work, and take fatigue to your prescriber. Do not buy it on the strength of 'two Nobel Prize winners', which is one laureate chairing an advisory board. And do not assume HSA/FSA eligibility without checking your plan. We earn 2.5% here, roughly a dollar on a $49 order, and this is one of the few supplement pages in this series where our honest conclusion is that the product is basically what it says it is — provided you read what the company tells its investors rather than what it tells you.
Read The Filing, Not The Advert.
The best-substantiated supplement we have reviewed — two FDA NDI reviews, GRAS, five national regulators, audited accounts. It proves it raises NAD+. It does not prove that helps.
Visit Tru NiagenCompare Other GLP-1 Providers
See how other telehealth providers stack up.
CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →Medical Disclaimer: This page is informational and is neither medical nor investment advice. Tru Niagen is a dietary supplement, not a medicine; it is not intended to diagnose, treat, cure or prevent any disease, is not a weight-loss aid, and is not a treatment for any side effect of GLP-1 medication. Raising a biomarker is not the same as improving health: evidence that nicotinamide riboside increases NAD+ concentrations does not establish that it improves energy, muscle function, metabolic health or the ageing process, and trials have returned mixed results on clinical endpoints. Persistent fatigue during weight-loss treatment has causes that can be identified and treated — inadequate intake, dehydration, iron or B12 deficiency, thyroid dysfunction, sleep disorders including obstructive sleep apnoea — and should be investigated by a clinician rather than supplemented against. Loss of lean mass during GLP-1 treatment should be managed with a clinician through adequate protein intake and resistance training. Anyone who is pregnant or breastfeeding, has a liver or kidney condition, is undergoing cancer treatment, or takes prescription medication should consult a clinician before starting any supplement; NAD+ precursors have been discussed in relation to cell proliferation and anyone with a current or previous cancer diagnosis should raise this with their oncology team specifically. Intravenous and injectable Niagen formulations referred to here are prescription products administered under clinical supervision and are not the same as the oral supplement; do not seek injectable products outside a licensed pharmacy or clinic. Financial information is included to help readers assess a company they may subscribe to and is not a recommendation to buy, hold or sell any security. Consult a licensed clinician before starting or changing any treatment or supplement.
Date reviewed: 8 August 2026. Prices and site claims were read from truniagen.com on that date and may change: Tru Niagen 300mg capsules, described as 'The original—our minimum daily recommended serving', $49.00 regular and from $39.20, in 30, 90 and 180 counts, rated 4.5 from 611 reviews; Tru Niagen Pro 1,000mg, 60 capsules, $116.00 and from $92.80, rated 4.7 from 192; Tru Niagen 150mg, 120 capsules, $94.00 and from $75.20, rated 4.7 from 20; Tru Niagen 300mg Stick Packs, 30 count, $58.00 and from $46.40, rated 4.1 from 8; Tru Niagen Beauty, a once-daily 100mg Niagen supplement with added actives, $49.00 and from $39.20. The site advertised 'Subscribe and save 20% off on all orders + free shipping, always' and stated that Tru Niagen now accepts HSA/FSA. Site claims recorded included '45+ Human Clinical Studies on Niagen® NR', '60+ Proprietary NR Patents', '500+ Published Scientific Studies', '300+ Global Research Collaborations', 'Backed by 25+ years of research & innovation' and 'a Nobel Prize-winning biochemist'; the affiliate material supplied to us described the product as 'backed by 2 Nobel Prize winners, 40+ patents, 300+ scientific studies, and 275+ global research collaborations' and as 'the nutrient that can revolutionize the way you age'. Per-day and per-year cost figures are our own arithmetic on the stated prices for the 300mg 30-count product taken once daily. Corporate and regulatory statements are quoted from the Form 10-K of Niagen Bioscience, Inc. for the fiscal year ended 31 December 2025, filed with the SEC on 4 March 2026 (CIK 1386570): total net sales of $129,423 thousand for 2025 against $99,597 thousand for 2024, an increase of 30% or $29.8 million, comprising Consumer Products $97,672 thousand (up 27%), Ingredients $28,675 thousand (up 45%) and Analytical reference standards and services $3,076 thousand (up 2%); Tru Niagen sales up $20.9 million or 27%, driven by a $16.2 million increase in e-commerce; a compound annual growth rate of 18% from 2021 to 2025; total stockholders' equity of $76,533 thousand and total liabilities and stockholders' equity of $106,406 thousand; an accumulated deficit of $164,528 thousand; and the risk-factor statement 'While we have recorded a net income in both 2025 and 2024, we may not be able to sustain profitability in future periods. Our history of net losses and negative cash flow have had, and may continue to have, an adverse effect on our stockholders' equity and working capital.' The filing further states that 'Data from numerous preclinical studies and human clinical trials demonstrate that orally administered NRC significantly increases NAD+ levels in blood and tissue'; that 'Food-grade Niagen® has twice been successfully reviewed under the FDA's new dietary ingredient (NDI) program, has been successfully notified to the FDA as GRAS, and has received approvals or authorizations from Health Canada, the European Commission, the Turkish Ministry of Agriculture, and the Therapeutic Goods Administration (TGA) of Australia', and has been approved for inclusion in medical foods by the Brazilian health regulator; that 'Food-grade Niagen® is authorized for human consumption as a dietary supplement and is generally recognized as safe (GRAS), while pharmaceutical-grade Niagen® is authorized by the U.S. Food and Drug Administration (FDA) for compounding by 503B outsourcing facilities'; that its 'Scientific Advisory Board, chaired by Dr. Roger Kornberg, Nobel Laureate and Stanford Professor, includes distinguished scientists such as Dr. Charles Brenner, discoverer of NR as an NAD+ precursor, and experts from Harvard, UC Davis, USC, Scripps Research, and the NIH'; and, as a risk factor, that 'In September 2025, the FDA determined that nicotinamide mononucleotide (NMN) may be lawfully marketed as a dietary ingredient. If this determination is not overturned or superseded, it may introduce additional channels of competition in certain product categories', alongside a warning that 'some competitors may engage in misleading marketing practices, including mislabeling their products by overstating ingredient levels'. SEC records confirm the registrant as Niagen Bioscience, Inc., formerly ChromaDex Corp., trading as NAGE on the Nasdaq Capital Market, with a quarterly report filed 4 August 2026; the cessation of trading under the former CDXC symbol in March 2025 reflected the name and ticker change rather than a delisting. We have not independently reviewed the underlying clinical trial reports referenced by the company. On HSA/FSA use, the IRS warned in March 2024 that a letter of medical necessity does not guarantee a product qualifies and that nutritional supplements generally do not meet the requirements for pre-tax health accounts; non-qualified HSA distributions are generally taxable and subject to an additional 20% penalty. The STEP 1 body-composition finding on lean mass is as published. Katalys offer #1282 lists 2.50% default commission and targets the United States.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This programme pays 2.50% of order value. This does not influence our editorial content or review ratings.